Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company

View Full Size

Download

Thumbnail JPEG, 116x70, 6.3 KB
Preview JPEG, 144x86, 8.6 KB
Small JPEG, 300x180, 20.4 KB
Full Size JPEG, 800x480, 54.6 KB

Smart Multimedia Gallery

Jeffrey B. Kindler, chief executive of Pfizer, left, and Bernard Poussot, chief executive of Wyeth, discuss the planned combination of their companies, announced in New York Monday, January 26, 2009. Pfizer agreed to acquire Wyeth, a research-based global pharmaceutical company, for $68 billion, creating the world's premier biopharmaceutical company. (Photo: Business Wire)